India’s pharmaceutical industry is poised for healthy revenue growth of 7–9% in FY26, according to the latest sector outlook from ICRA, even as challenges in the United States market weigh on overall performance.
Domestic Market Remains the Growth Engine
ICRA expects the Indian domestic market to expand by 8–10% in FY26, supported by:
*Expansion of sales forces and improved productivity of medical representatives
*Wider rural distribution networks
A steady pipeline of new product launches
“The domestic market continues to be a key growth driver for Indian pharma companies. Sales force expansion, improved productivity of medical representatives, deeper rural distribution, and new product launches are expected to support 8–10% revenue growth in FY2026 in the domestic market,” said Kinjal Shah, Senior Vice President & Co-Group Head, ICRA. ICRA noted that companies in its sample set have already reported 10.3% year-on-year growth in Q1 FY26, following 11.6% growth in FY25. Chronic therapies, new launches, and price hikes have fueled the momentum, even as volumes for branded generics remain subdued.
Policy Measures to Boost Affordability
ICRA noted that recent government initiatives, including GST exemptions and rate cuts on select lifesaving drugs and medical supplies, will improve affordability, strengthen healthcare inclusion, and further support steady demand in the domestic market.
US Outlook Turns Cautious
In contrast, the US market faces challenges. After growing 9.9% in FY25, revenues are expected to slow to 3–5% in FY26 due to pricing pressures and weaker sales.
ICRA highlighted additional hurdles:
*Regulatory scrutiny by the US FDA has resulted in warning letters, import alerts, and product launch delays.
*Compliance issues have triggered penalties and remediation costs, putting profit margins under strain.
The agency also flagged policy risks, including the US government’s proposal for a “most favoured nation” pricing policy and the recently imposed 50% tariffs on Indian imports across multiple sectors. While pharmaceuticals are currently exempt, the sector remains vulnerable to future trade actions.
Europe Maintains Double-Digit Growth
Europe is expected to remain a bright spot, with 10–12% growth in FY26, following a sharp 18.9% surge in FY25. Rising demand and stable pricing dynamics are likely to sustain the region’s strong performance.
Increased R&D Investments Signal Long-Term Focus
ICRA also noted that Indian pharmaceutical companies are stepping up research and development spending to 6–7% of revenues. The focus is shifting toward complex molecules and specialty products, underscoring the industry’s efforts to build long-term capabilities and resilience.
Outlook: Resilient Growth Amid Global Pressures
MSN.com reports that, despite global headwinds—particularly in the US—India’s pharma sector will post resilient growth in FY26. Strong domestic demand, supportive policy measures, and robust performance in Europe will help offset pressures, keeping the industry on track for a 7–9% revenue expansion.
